IBA - First proton therapy contract of the year
• IBA announced the sale of a new ProteusONE system to be installed in Connecticut, US• This is the first system sold in 2024. The first downpayment has been received and the company indicates that the price for a ProteusONE system, with a multi-year maintenance contract, ranges between EUR 40-50m. Margins should reflect the fact that Varian exited the market• We believe that Better-than-expected FY23 results and the improvements foreseen over FY24e will reassure the market and trigger a rerating. We foresee 4 main drivers for the share price over the next 12 months: 1/ new PT contracts, 2/ updateIBA- Ion Beam Applications develops and markets technologies and pharmaceutical products for the healthcare sector, with a focus on cancer diagnosis and therapy. Co. is also engaged in the sterilization and ionization market. Co. operates in two primary business segments: Equipment and Pharmaceuticals. Co.'s Equipment segment encompasses development, fabrication, and services associated with medical and industrial particle accelerators, proton therapy systems, and a range of dosimetry products, while Co.'s Pharmaceuticals segment encompasses the production and distribution of radiopharmaceutical agents as well as its bioassay operations.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.